Efficacy and nephrotoxicity of polymyxin B in elderly patients with carbapenem resistant bacterial infection

Ann Clin Microbiol Antimicrob. 2023 Nov 15;22(1):101. doi: 10.1186/s12941-023-00647-2.

Abstract

Background: To study the efficacy and nephrotoxicity of polymyxin B in the treatment of elderly patients with carbapenem-resistant organism (CRO) infection.

Methods: The clinical and microbiological data of patients with CRO-infected sepsis treated with polymyxin B were retrospectively analyzed. The effective rate, bacterial clearance, incidence and recovery rate of acute renal injury (AKI) and prognosis-related indicators in AKI at different stages were compared.

Results: The effective rate of 215 elderly patients with CRO infection treated with polymyxin was 50.7%. The total bacterial clearance rate was 44.2%, the total incidence of AKI was 37.2%, the recovery rate of AKI was 35%, and the incidence range of polymyxin B-related AKI was 10.2-37.2%. Logistic multivariate regression analysis showed that the predictors of AKI in elderly patients were high APACHE II score, long duration of polymyxin, chronic renal insufficiency and ineffective outcome; the ROC curve showed that the cutoff value for predicting AKI was a serum creatinine concentration of 73 mmol/L before polymyxin B use, and the AUC was 0.931.

Conclusions: Rational use of polymyxin B is safe and effective in elderly patients with CRO infection, and its effective outcome can improve the recovery rate of AKI.

Keywords: Acute kidney injury; Carbapenem-resistant organism; Elderly; Infection; Polymyxin B.

MeSH terms

  • Acute Kidney Injury* / chemically induced
  • Aged
  • Anti-Bacterial Agents / adverse effects
  • Bacterial Infections* / drug therapy
  • Carbapenems / adverse effects
  • Humans
  • Polymyxin B / adverse effects
  • Retrospective Studies

Substances

  • Polymyxin B
  • Anti-Bacterial Agents
  • Carbapenems